Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Biasoni

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 28, 2022
Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumorsSebastiano Nazzani, Silvia Stagni, Davide Biasoni, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Clinical Genitourinary Cancer|April 8, 2025
mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up)Alberto Macchi, Martina Bruniera, Sebastiano Nazzani, et al.
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
JCO Precision Oncology|August 18, 2025
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to AbemaciclibAmedeo Nuzzo, Marco Barella, Melanie Claps, et al.
British Journal of Cancer|April 9, 2026
Salvage post-chemotherapy retroperitoneal lymph-node dissection: evolving paradigm for marker-positive non-seminomatous germ-cell tumors managementSebastiano Nazzani, Carlo Silvani, Cesare Saitta, et al.
Minerva Urology and Nephrology|January 27, 2026
Management of monorchid patients with previous testis cancer: the role of frozen sections and the real possibility of testis sparing surgery in a large retrospective seriesSebastiano Nazzani, Ruggero Darisi, Mario Catanzaro, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2025
Clinical evaluation of the role of miRNA 371 in small testicular masses. Results of the "S1STeM 371" TrialSebastiano Nazzani, Adele Busico, Valentina Bernasconi, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|August 28, 2022
Laparoscopic retroperitoneal lymph-node dissection in metastatic nonseminomatous germ-cell tumorsSebastiano Nazzani, Silvia Stagni, Davide Biasoni, et al.
Clinical Genitourinary Cancer|May 3, 2014
Interim fluorine-18 fluorodeoxyglucose positron emission tomography for early metabolic assessment of therapeutic response to chemotherapy for metastatic transitional cell carcinomaPatrizia Giannatempo, Alessandra Alessi, Rosalba Miceli, et al.
Clinical Genitourinary Cancer|April 8, 2025
mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up)Alberto Macchi, Martina Bruniera, Sebastiano Nazzani, et al.
Clinical Genitourinary Cancer|September 7, 2014
Immunohistochemistry to enhance prognostic allocation and guide decision-making of patients with advanced urothelial cancer receiving first-line chemotherapyAndrea Necchi, Patrizia Giannatempo, Biagio Paolini, et al.
Clinical Genitourinary Cancer|July 22, 2014
A prognostic model including pre- and postsurgical variables to enhance risk stratification of primary mediastinal nonseminomatous germ cell tumors: the 27-year experience of a referral centerAndrea Necchi, Patrizia Giannatempo, Salvatore Lo Vullo, et al.
JCO Precision Oncology|August 18, 2025
Targeting Cyclin-Dependent Kinase 4 Amplifications: A Pioneering Case of Metastatic Leydig Cell Tumor Responding to AbemaciclibAmedeo Nuzzo, Marco Barella, Melanie Claps, et al.
British Journal of Cancer|April 9, 2026
Salvage post-chemotherapy retroperitoneal lymph-node dissection: evolving paradigm for marker-positive non-seminomatous germ-cell tumors managementSebastiano Nazzani, Carlo Silvani, Cesare Saitta, et al.
Minerva Urology and Nephrology|January 27, 2026
Management of monorchid patients with previous testis cancer: the role of frozen sections and the real possibility of testis sparing surgery in a large retrospective seriesSebastiano Nazzani, Ruggero Darisi, Mario Catanzaro, et al.
Urologic Oncology|May 20, 2015
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogationDaniele Raggi, Luigi Mariani, Patrizia Giannatempo, et al.
European Journal of Cancer (Oxford, England : 1990)|May 18, 2025
Clinical evaluation of the role of miRNA 371 in small testicular masses. Results of the "S1STeM 371" TrialSebastiano Nazzani, Adele Busico, Valentina Bernasconi, et al.
Pageof 7